The trial is open for inclusion of patients above 18 years who are scheduled for curative treatment of colorectal cancer liver metastases. The patients are randomized to either acetylsalicylic acid (ASA) 160 mg daily or placebo one tablet daily for three years.
Individuals cannot take part in the study if they regularly take aspirin, non-steroidal anti-inflammatory drugs (NSAIDs, e.g. ibuprofen), corticosteroids, anti-coagulants (e.g. warfarin or heparin), or other medications that can increase bleeding risk. They can also not be included if they are at risk of developing side effects from aspirin (e.g. a stomach ulcer) or have an inherited bleeding disorder. Patients with severe kidney or heart failure or liver cirrhosis can also not participate.